MX2021000051A - Inhibidores de triazol glicolato oxidasa. - Google Patents

Inhibidores de triazol glicolato oxidasa.

Info

Publication number
MX2021000051A
MX2021000051A MX2021000051A MX2021000051A MX2021000051A MX 2021000051 A MX2021000051 A MX 2021000051A MX 2021000051 A MX2021000051 A MX 2021000051A MX 2021000051 A MX2021000051 A MX 2021000051A MX 2021000051 A MX2021000051 A MX 2021000051A
Authority
MX
Mexico
Prior art keywords
oxidase inhibitors
glycolate oxidase
triazole
useful
pharmaceutically acceptable
Prior art date
Application number
MX2021000051A
Other languages
English (en)
Inventor
Robert Zamboni
Hans Maag
Miguel Xavier Fernandes
Elham Akbariromani
Marc- Andre Beaulieu
Yves Leblanc
Pallavi Thakur
Original Assignee
Cantero Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantero Therapeutics Inc filed Critical Cantero Therapeutics Inc
Publication of MX2021000051A publication Critical patent/MX2021000051A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La presente invención proporciona ácidos carboxílicos de triazol y compuestos relacionados, y también sales farmacéuticamente aceptables de estos, que son útiles como inhibidores de glicolato oxidasa. También se describen las composiciones farmacéuticas y los métodos para tratar la hiperoxaluria primaria, tipo I (f) y cálculos renales.
MX2021000051A 2018-07-06 2019-07-05 Inhibidores de triazol glicolato oxidasa. MX2021000051A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862694918P 2018-07-06 2018-07-06
US201962827573P 2019-04-01 2019-04-01
PCT/US2019/040690 WO2020010309A1 (en) 2018-07-06 2019-07-05 Triazole glycolate oxidase inhibitors

Publications (1)

Publication Number Publication Date
MX2021000051A true MX2021000051A (es) 2021-03-25

Family

ID=67441692

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000051A MX2021000051A (es) 2018-07-06 2019-07-05 Inhibidores de triazol glicolato oxidasa.

Country Status (14)

Country Link
US (2) US11401246B2 (es)
EP (1) EP3817816A1 (es)
JP (1) JP7348705B2 (es)
KR (1) KR20210041564A (es)
CN (1) CN112399873A (es)
AU (1) AU2019297523A1 (es)
BR (1) BR112021000050A2 (es)
CA (1) CA3104529A1 (es)
CO (1) CO2021001277A2 (es)
IL (1) IL279952A (es)
MX (1) MX2021000051A (es)
PE (1) PE20210859A1 (es)
SG (1) SG11202012930RA (es)
WO (1) WO2020010309A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210041564A (ko) 2018-07-06 2021-04-15 오판 바이오테크 인코포레이티드 트리아졸 글리콜레이트 옥시다아제 억제제
CA3155577A1 (en) 2019-11-01 2021-05-06 GyanRx Sciences, Inc. Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
AU2021205916A1 (en) * 2020-01-08 2022-08-25 Cantero Therapeutics, Inc. Processes for preparing triazole glycolate oxidase inhibitors
WO2022066933A1 (en) * 2020-09-24 2022-03-31 Chinook Therapeutics Canada, Inc. Pentafluoro-sulfanyl -substituted triazolyl compounds and methods of use thereof
TW202339727A (zh) * 2021-10-11 2023-10-16 美商坎特羅治療股份有限公司 使用１ｈ－１，２，３－***－４－羧酸之治療方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0774218B2 (ja) * 1987-03-02 1995-08-09 第一製薬株式会社 ベンゾピラノトリアゾ−ル誘導体
US6187326B1 (en) 1998-12-29 2001-02-13 Thomas T. Yamashita Soil amendment composition
US7022702B2 (en) 2000-04-07 2006-04-04 Qlt Inc. Antiproliferative 1,2,3-thiadiazole compounds
WO2005051301A2 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
CN104159891B (zh) 2012-01-10 2016-09-07 霍夫曼-拉罗奇有限公司 哒嗪酰胺化合物和它们作为syk 抑制剂的用途
JP5455279B1 (ja) 2012-10-25 2014-03-26 アサヒグループホールディングス株式会社 ラテックスの増産方法
TW201437200A (zh) 2013-01-15 2014-10-01 Intermune Inc 溶血磷脂酸受體拮抗劑
US9392796B2 (en) 2013-03-15 2016-07-19 Spogen Biotech Inc. Plant growth-promoting bacteria and methods of use
FR3021843B1 (fr) 2014-06-06 2016-07-08 Lesaffre & Cie Methode et composition pour ameliorer la productivite de plantes non legumineuses
JP5866035B1 (ja) 2015-01-08 2016-02-17 アサヒグループホールディングス株式会社 有効分げつ促進方法
CN107404883A (zh) 2015-03-19 2017-11-28 兴人生命科学株式会社 具有植物生长促进或根伸长促进效果且附加值提高效果的酵母抽提物
US20200262794A1 (en) 2015-12-07 2020-08-20 Wake Forest University Health Sciences Glycolate oxidase inhibitors and methods of use for the treatment of kidney stones
TW202340155A (zh) * 2017-12-29 2023-10-16 美商拜奧馬林製藥公司 用於疾病治療之乙醇酸酯氧化酶抑制劑
WO2019133813A1 (en) 2017-12-29 2019-07-04 Orfan Biotech Inc. Glycolate oxidase inhibitors and use thereof
US11389456B2 (en) 2018-02-23 2022-07-19 Oxalurx, Inc. Compounds and methods for treating oxalate-related diseases
KR20210041564A (ko) 2018-07-06 2021-04-15 오판 바이오테크 인코포레이티드 트리아졸 글리콜레이트 옥시다아제 억제제
BR112021025781A2 (pt) 2019-06-19 2022-03-03 Biomarin Pharm Inc Composto, composição farmacêutica, método de tratamento de uma doença ou transtorno associado com um defeito no metabolismo de glioxilato, método de tratamento de uma doença ou transtorno associado com a enzima glicolato oxidase (go) ou alterações no metabolismo de oxalato e método para inibição da enzima go

Also Published As

Publication number Publication date
CN112399873A (zh) 2021-02-23
AU2019297523A1 (en) 2021-02-25
US20210403439A1 (en) 2021-12-30
JP2021530560A (ja) 2021-11-11
WO2020010309A1 (en) 2020-01-09
US20230143491A1 (en) 2023-05-11
EP3817816A1 (en) 2021-05-12
KR20210041564A (ko) 2021-04-15
CO2021001277A2 (es) 2021-04-30
PE20210859A1 (es) 2021-05-18
US11401246B2 (en) 2022-08-02
SG11202012930RA (en) 2021-01-28
BR112021000050A2 (pt) 2021-04-06
WO2020010309A9 (en) 2020-01-30
JP7348705B2 (ja) 2023-09-21
CA3104529A1 (en) 2020-01-09
IL279952A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
MX2021000051A (es) Inhibidores de triazol glicolato oxidasa.
PH12021500014A1 (en) Fused ring compounds
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
MX2022002938A (es) Compuestos inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) cooperativos para metiltioadenosina (mta).
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
WO2015200680A8 (en) Prmt5 inhibitors and uses thereof
PH12016501344A1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
NZ763551A (en) Compounds useful for inhibiting cdk7
EA201991884A3 (ru) Ингибиторы g12c kras
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
AU2020281332A8 (en) Dna-dependent protein kinase inhibitor
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
PH12021500008A1 (en) Transglutaminase 2 (tg2) inhibitors
MX2021011606A (es) Compuestos dirigidos a prmt5.
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
MX2021012423A (es) Métodos y composiciones para degradación de proteínas específicas.
NZ788133A (en) Cd73 inhibitors
WO2018035346A8 (en) KINASE INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CANCER
PH12021550883A1 (en) Crystalline salts of a plasma kallikrein inhibitor
WO2021026479A9 (en) Small molecule inhibitors of s1p2 receptor and uses thereof
MX2023005530A (es) Metodos y composiciones que comprenden un inhibidor de krasg12c y un antagonista de union a pd-l1 para tratar cancer de pulmon.
PH12021550323A1 (en) Dendrimer formulations
MX2020010156A (es) Inhibidores de la secrecion de proteina cdp.
EA201990196A1 (ru) Пиридопиримидиноновые ингибиторы cdk2/4/6